KBC Group
KRYS icon

KBC Group’s Krystal Biotech KRYS Stock Holding History

KBC Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Hold
685
– – ﹤0.01% 961
2026
Q1 		$177K Hold
685
– – ﹤0.01% 1021
2025
Q4 		$169K Hold
685
– – ﹤0.01% 985
2025
Q3 		$121K Hold
685
– – ﹤0.01% 1154
2025
Q2 		$94K Sell
685
-254
-27% -$37.3K ﹤0.01% 1235
2025
Q1 		$169K Hold
939
– – ﹤0.01% 1165
2024
Q4 		$147K Buy
939
+297
+46% +$52.7K ﹤0.01% 1312
2024
Q3 		$117K Buy
642
+132
+26% +$25.5K ﹤0.01% 1186
2024
Q2 		$94K Buy
510
+37
+8% +$6.21K ﹤0.01% 1212
2024
Q1 		$84K Hold
473
– – ﹤0.01% 1222
2023
Q4 		$59K Hold
473
– – ﹤0.01% 1398
2023
Q3 		$55K Buy
+473
New +$57.7K ﹤0.01% 1376
2021
Q4 		– Sell
-1,975
Closed -$103K – 1311
2021
Q3 		$103K Hold
1,975
– – ﹤0.01% 1159
2021
Q2 		$134K Hold
1,975
– – ﹤0.01% 1136
2021
Q1 		$152K Hold
1,975
– – ﹤0.01% 1130
2020
Q4 		$119K Hold
1,975
– – ﹤0.01% 1133
2020
Q3 		$85K Hold
1,975
– – ﹤0.01% 1136
2020
Q2 		$82K Buy
1,975
+1,600
+427% +$77K ﹤0.01% 1173
2020
Q1 		$16K Hold
375
– – ﹤0.01% 1262
2019
Q4 		$21K Sell
375
-5,390
-93% -$264K ﹤0.01% 1452
2019
Q3 		$200K Buy
5,765
+2,490
+76% +$111K ﹤0.01% 1251
2019
Q2 		$132K Hold
3,275
– – ﹤0.01% 1286
2019
Q1 		$108K Buy
3,275
+350
+12% +$8.25K ﹤0.01% 1270
2018
Q4 		$61K Buy
2,925
+700
+31% +$14.7K ﹤0.01% 1200
2018
Q3 		$39K Hold
2,225
– – ﹤0.01% 1342
2018
Q2 		$33K Hold
2,225
– – ﹤0.01% 1248
2018
Q1 		$22K Buy
2,225
+1,225
+123% +$12.1K ﹤0.01% 1248
2017
Q4 		$11K Buy
+1,000
New +$10K ﹤0.01% 1245

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

KBC Group's KRYS Position: Q2 2026 in Review

KBC Group held its Krystal Biotech (KRYS) position steady in Q2 2026 at 685 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #961.

KBC Group first reported a position in KRYS in Q4 2017 and has held it in 28 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • KBC Group held 685 shares of Krystal Biotech worth $255K as of Q2 2026.
  • KBC Group left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #961 holding.
  • KBC Group first reported a position in Krystal Biotech in Q4 2017 and has held it in 28 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.